New Data Highlights Etrasimod’s Potential for Atopic Dermatitis
Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, offers promise as a new therapeutic option for atopic dermatitis, according to a late-breaking study presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021.

Press Release
Mount Sinai Experts Author Landmark ‘Seminar’ on Atopic Dermatitis (Eczema) in The Lancet
Feb 13, 2025 View All Press Releases